Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chattem/J&J deal closes

This article was originally published in The Tan Sheet

Executive Summary

Chattem announces Jan. 2 it closed its agreement to acquire the U.S. rights to ACT, Unisom, Cortizone, Kaopectate and Balmex brands for $410 mil. in cash. The acquired brands were divested in connection with J&J's acquisition of Pfizer's Consumer Healthcare business (1"The Tan Sheet" Dec. 18, 2006, p. 9 and 2"The Tan Sheet" Oct. 9, 2006, p. 6). "We are very excited to add these leading brands to the company's existing portfolio of quality products," Chattem CEO and Chairman Zan Guerry says. In related news, Standard & Poor's says Chattem will replace Fidelity Bankshares in the S&P SmallCap 600 index after the close of trading Jan. 5...

You may also be interested in...

Chattem Flexes Earnings Guidance After Strong Start For Core Brands

Strong sales in January and high expectations for product initiatives planned for the remainder of the year prompted Chattem to increase its fiscal 2008 earnings estimates, the firm's executives told analysts Jan. 29

Chattem Hopes Brands Acquired From J&J Offset Cool Sales Of Pro-Therapy

For 2007, Chattem expects sales of products recently acquired from Johnson & Johnson to rival its existing "big three," of Gold Bond skin care, Icy Hot topical analgesics and Selsun medicated shampoos

J&J, Pfizer Satisfy FTC Conditions To Clear Deal; EC Signs Off

Johnson & Johnson and Pfizer's divestiture of the Zantac, Cortizone, Unisom and Balmex brands satisfies the Federal Trade Commission's anticompetitive complaint about J&J's acquisition of Pfizer's consumer healthcare business

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts